PEMODELAN ARSITEKTUR SISTEM PENGAWASAN PRODUK TERAPETIK MENGGUNAKAN KERANGKA TOGAF BERBASIS SERVICE ORIENTED ARCHITECTURE

• Main Authors: , WINAYU BUDI WARDHANI, , Ir. Lukito Edi Nugroho, M.Sc., Ph.D
• Format: Theses and Dissertations NonPeerReviewed
• Published: [Yogyakarta] : Universitas Gadjah Mada 2014
• Subjects: ETD
• Online Access: https://repository.ugm.ac.id/133260/; http://etd.ugm.ac.id/index.php?mod=penelitian_detail&sub=PenelitianDetail&act=view&typ=html&buku_id=73828
• Institution: Universitas Gadjah Mada

GMP Inspectorate is part of the The National Agency of Drug and Food Control which have supervision on therapeutic products, both pre and post-market. One of the strategies on internal policy and Renstra document is strengthening ICT towards integrated supervision. However at this time to integrate between directorate in order to support business process of therapeutic supervision is still a challenge. To facilitate supervision process of therapeutic products, the exchange and the availability of information between directorates is needed. Meanwhile, the development of information system is limited in the internal GMP Inspectorate only. To facilitate those problems, specially in the supervision process of therapeutic products, this research has been proposed an architecture solution. The architecture is built using two methods, which are SSM as a research structure and TOGAF as an EA framework. To optimize the benefits of EA, this study uses the concept of SOA in interpreting business services into technology. Researchers use TOGAF version 9.1 which offers one package design tools that support SOA. SOA is needed in order to build data services that required by supervision process of therapeutic products. The proposed model of EA, resulted in four architectural. Architecture are vision architecture, business architecture contains 9 business areas supervisory, 24 business functions and 25 information service, also information systems architecture that produces 9 blocks system with 30 applications and the last is technology architecture. This proposed EA is also accompanied by guidances that can be provided as recommendations to support the implementations of supervision system of therapeutic products, represented in the opportunities and solution, migration planning, implementation governance and change management